Double-digit growth of medium-large products such as Rovazet, Crezet, and Daviduo
In the first quarter of last year, the outpatient prescription market shrank significantly due to the third wave of COVID-19, but the growth of Ezetimibe + Statin combination drugs has not withered.
As Newsmp tallied the outpatient prescription of major Statin + Ezetimibe combination therapies, most of them have continued to grow in double digits.
Rosuzet (Hanmi Pharmaceutical), with a quarterly prescription amount of 20 billion won mark, grew 16.3% in 1Q and recorded 26.6 billion won in prescription, showing a green light to enter the 100 billion mark a year that was not achieved last year.
Through the growth of medium-large drugs centered on Rosuzet, the market size of Ezetimibe + Statin combination therapy also exceeded 120 billion won, continuing a double-digit growth trend.
In particular, the market is expected to expand further as new products are pouring into the Atorvastatin + Ezetimibe combination market, which was preserved by Atozet (MSD) alone.
However, Atozet, which ranks second in the Ezetimibe + Statin combination therapy market, grew only 1.4% in the first quarter.
Along with Rosuzet and Atozet, Rosuvamibe (Yuhan Corporation), with a 10 billion won mark, also remained at 0.8% growth.
Meanwhile, Rovazet (HK inno.N) grew 15.5%, reaching the 7 billion won mark, Crezet (Daewoong Pharmaceutical) 28.4%, and Daviduo (GC Pharma) 64.8%, exceeding 5 billion won.
On the other hand, Vytorin (MSD), the original Ezetimibe + Statin combination therapy, has steadily decreased its prescription amount, retreating from the 5 billion mark in the first quarter.
Rather, Esuba (Huons), which recorded 3.4 billion won in 1Q of last year, grew to 4.3 billion won, closely following Vytorin.
Roze Duo (Jeil Pharmaceutical) also grew more than 50% from 2.5 billion won to 3.8 billion won, reaching the 4 billion won mark, and Crestibe (Hutecs) nearly touched the 3 billion mark as well with a 20% growth.
Contrarily, Cretrol (Aju Pharm) showed a 20% contraction from 2.5 billion won to 2.1 billion won.
Lypsta Plus (Abbott) achieved 1.8 billion won, Clowzet (Daewon Pharm) and Ezerosu (Shin Poong Pharm.) 1.7 billion won, Rostorin (Hana Pharmaceutical) 1.6 billion won, Credouble (Hanlim Pharm.) 1.5 billion won, Ezerova (Kukje Pharma) and Suvazet (Ahngook Pharmaceuticals) 1.2 billion won, and Rosueze (Kyongbo Pharmaceutical) 1.1 billion won.
